4D Molecular Therapeutics reports positive 2-year Phase 2b PRISM data for 4D-150 in wet AMD
FDMT•2-year PRISM Phase 2b results
4D Molecular Therapeutics reported positive 2-year PRISM Phase 2b results for 4D-150 in wet age-related macular degeneration on July 18, 2026.
- Data were already presented as a 2-year readout using a May 18, 2026 cutoff.
- Patients maintained vision outcomes and retinal anatomy control over two years, supporting durability from a single intravitreal dose.
- Results indicated a sustained reduction in follow-on injection needs versus standard aflibercept dosing, reinforcing the Phase 3 development strategy.
- Safety remained supportive for the Phase 3 dose, with limited early mild inflammation and no new inflammation signals in longer follow-up.
